Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on ...

Targeting receptors for erythropoietin on dendritic cells may be a viable strategy for treating MS and other diseases, ...

A single signaling pathway controls whether immune cells attack or befriend cells they encounter while patrolling our bodies, ...

This article explores how the role of regulatory T cells in immunological self-tolerance evolved from skepticism to Nobel ...

Targeting receptors for erythropoietin on dendritic cells may be a viable strategy for treating MS and other diseases, ...

Hepatocellular carcinoma (HCC) is the sixth leading cause of cancer-related mortality worldwide.1 Despite therapeutic ...

Egle Therapeutics SAS (Egle), a clinical-stage biotechnology company developing precision medicines that modulate regulatory T cells (Tregs) to restore immune balance, today announced dosing of the ...

Selective Treg modulator gotistobart (BNT316/ONC-392) showed a reduction in the risk of death by more than half compared to standard of care ...

This study provides useful insights into addressing the question of whether the prevalence of autoimmune disease could be driven by sex differences in the T cell receptor (TCR) repertoire, correlating ...

This year's two Japanese Nobel Prize winners spoke at separate venues in Stockholm ahead of Wednesday's Nobel Prize award ...